SCM
TARA icon

Soleus Capital Management’s Protara Therapeutics TARA Stock Holding History

Soleus Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,093
Closed -$390K – 80
2020
Q4 		$390K Sell
16,093
-83,907
-84% -$1.81M 0.05% 63
2020
Q3 		$1.68M Buy
+100,000
New +$2.32M 0.89% 34

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Soleus Capital Management's TARA Position: Q1 2021 in Review

Soleus Capital Management sold out of Protara Therapeutics (TARA) in Q1 2021, closing a stake of 16,093 shares — an estimated $390K sold.

Soleus Capital Management first reported a position in TARA in Q3 2020 and held it in 2 quarters. The position peaked at $1.68M in Q3 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q1 2021.

  • Soleus Capital Management reported no remaining Protara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Soleus Capital Management sold 16,093 Protara Therapeutics shares in Q1 2021, an estimated $390K.
  • Soleus Capital Management first reported a position in Protara Therapeutics in Q3 2020 and held it in 2 quarters.
  • Soleus Capital Management's Protara Therapeutics position peaked at $1.68M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2021.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.